Lacklustre Performance Is Driving Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Low P/S
Capricor Reports Positive Long-term Data for DMD Drug Deramiocel
Capitulation in Biotech Is Near, as Well as a Rally – Piper Sandler
Entrada Therapeutics Presents New Data Supporting Its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
Capricor Stock Rallies 20% on DMD Data Presentation Update
Express News | Entrada Therapeutics Promotes Natarajan Sethuraman, Phd, to President of Research and Development